An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Hematologic Malignancies.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Afuresertib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 15 Sep 2017 Planned End Date changed from 18 Dec 2017 to 18 Apr 2018.
- 15 Sep 2017 Planned primary completion date changed from 18 Dec 2017 to 18 Apr 2018.
- 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.